# Pulsed electromagnetic fields may be effective for the management of primary

2 osteoporosis: a systematic review and meta-analysis

- 4 Siyi Zhu<sup>a,b</sup>, Yi Li<sup>a,b</sup>, Liqiong Wang<sup>a,b</sup>, Jinming Huang<sup>a,b</sup>, Kangping Song<sup>a,b</sup>, Xinling Gan<sup>a,b</sup>,
- 5 Xiaona Xiang<sup>a,b</sup>, Chengqi He<sup>a,b\*</sup>, Lin Yang<sup>a,b\*</sup>
- <sup>a</sup>Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan,
- 8 China.

1

3

6

11

15

- 9 <sup>b</sup>Rehabilitation Medicine key laboratory of Sichuan Province, West China Hospital, Sichuan
- 10 University, Chengdu, Sichuan, China.
- \*Corresponding author: Dr. Chengqi He or Dr. Qiang Gao or Dr. Lin Yang at the Rehabilitation
- 13 Medical Center, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Wuhou
- District, 610041, Chengdu, China. Email: hxkfhcq@126.com (CH) or 5648197@qq.com (LY).
- 16 **Abbreviated title**: Pulsed electromagnetic fields for primary osteoporosis
- 17 **Key words**: Osteoporosis, Electromagnetic Fields; Bone Density; Physical Therapy
- Modalities; Disability Evaluation
- 19 **Word Count**: 350 words (Abstract)
- 20 3735 words (Main text)

**ABSTRACT** 

22

- Objective: To investigate the effectiveness of pulsed electromagnetic fields (PEMFs) for the
- 24 management of primary osteoporosis in older adults.
- 25 **Design:** Systematic review and meta-analysis.
- 26 **Data Sources:** MEDLINE, EMBASE, Web of Science, CENTRAL and CCTR, Physiotherapy
- 27 Evidence Database, CNKI, VIP, Wan Fang, ClinicalTrials.gov and Current controlled trials from
- the inception dates to April 30, 2021.
- 29 **Eligibility criteria for study selection:** Randomised controlled trials or quasi-randomised trials
- 30 examining the effects of PEMFs compared to placebo or sham or other agents for the
- 31 management of primary osteoporosis (including those with previous fractures).
- 32 **Data extraction and synthesis:** Two independent reviewers extracted data. Primary outcomes
- were bone mass and number of incident fractures. Secondary outcomes were functional
- 34 assessments, quality of life, and adverse events. Risk of bias was assessed with the Cochrane
- 35 Collaboration's tool and certainty of evidence with the grading of recommendations assessment,
- development and evaluation (GRADE) framework. A random effects model was used to calculate
- mean differences and 95% confidence intervals.
- 38 **Results:** Eight trials including 396 participants met the inclusion criteria. Low certainty evidence
- 39 showed that PEMFs was non-inferior to conventional pharmacological agents in preventing the
- 40 decline of Bone Mineral Density (BMD) at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur
- 41 neck (MD 0.01; CI -0.02 to 0.04), and improving balance function measured by Berg Balance
- 42 Scale (BBS) (MD 0.01; CI -0.09 to 0.11) and Timed Up and Go test (MD -0.04; CI -0.80 to 0.72),
- 43 directly after intervention. The similar effects were observed in BMD and BBS at 12- and 24-
- 44 weeks follow-up from baseline with moderate certainty evidence. Very low certainty evidence
- showed that PEMFs (versus exercise) had small but significant effect on BMD at the femur neck
- 46 (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 to 0.35).
- 47 **Conclusion:** PEMFs had positive effects non-inferior to first-line treatment on BMD and balance
- 48 function in older adults with primary osteoporosis, but with low to very low certainty evidence
- and short-term follow-ups. There is a need for high-quality randomised controlled trials
- evaluating PEMFs for the management of primary osteoporosis.
- 51 **Registration:** PROSPERO CRD42018099518.

# INTRODUCTION Osteoporosis is a systemic and multifactorial skeletal disorder characterized by low bone mineral density and skeletal fragility that occur with aging, with a consequent increase of susceptibility to

low-trauma fractures <sup>1</sup>. The most prevalent symptoms of osteoporosis are fractures at vertebrae,

proximal femur (hip), and wrist affecting patients' physical function and quality of life. It is

estimated that over 200 million people worldwide are affected by osteoporosis, accounting for 8.9

million fractures annually <sup>2</sup>. The possibility of osteoporotic fractures exceeds 40% and the

probability of hip fracture alone could target 20% in white female population over 50 years old <sup>3</sup>.

61 In China, a higher incidence of hip fractures in men than in women was reported <sup>4</sup>. Each year,

osteoporotic fractures account for over 432,000 hospitalizations and 2.5 million medical visits in

the USA <sup>5</sup>. The treatment costs for fractures were recorded at nearly \$17 billion in the USA in

2005 <sup>6</sup>, and €31.7 billion in Europe in 2000 <sup>7</sup>. Therefore, osteoporosis has been identified as a

major health burden globally by WHO, due to its high prevalence, disability rate, related

66 mortality and poor quality of life <sup>8</sup>.

53

54

55

56

57

58

59

60

62

63

64

65

68

69

70

71

72

73

77

80

82

83

Rehabilitation interventions given its important roles in modifying risk factors related to fractures,

restoring function and improving quality of life are frequently recommended as an option in the

nonpharmacological management of osteoporosis <sup>9,10</sup>. Pulsed electromagnetic fields (PEMFs) at a

specific intensity and frequency have been proved effective in attenuating bone loss and the relief

of pain and discomfort after osteoporosis. As we reviewed elsewhere <sup>11</sup>, PEMFs were found to be

positive at promoting bone formation by stimulating the formation and differentiation of

osteoblasts, and negative at inhibiting the function of osteoclasts in bone resorption.

Experimental studies suggest that PEMFs may exert effects on Ca<sup>2+</sup>-related receptors on the bone

75 cell membrane which play a regulatory role in the maintenance of bone remodelling <sup>12</sup>. Further,

76 the exposure of PEMFs could influence the physiopathology of osteoporosis by targeting

inflammation and potentially relieving pain via these regulatory processes and improvements in

bone remodeling <sup>13</sup>.

79 PEMFs have been widely used as an clinical option for the management of pain and discomfort

related to osteoporosis since the introduce of its usage for non-union fractures was approved by

81 FDA in 1979 <sup>14</sup>. However, clinical trials evaluating the effectiveness of PEMFs have been

conducted with inconsistent results, to which parameters of PEMFs used in studies, follow-up

time points and clinical settings differ across studies may lead <sup>11</sup>. In order to expand upon the

- 84 current knowledge on whether PEMFs is an effective physical agent for osteoporosis clinically, a
- 85 systematic review and meta-analysis of clinical trials was performed to compare PEMFs with
- placebo or sham or other agents for the management of primary osteoporosis in older adults.

## **METHODS**

87

88

93

94

- 89 This systematic review and meta-analysis was conducted in accordance with the Cochrane
- 90 Handbook for Systematic Reviews of Interventions <sup>15</sup> and reported based on Preferred Reporting
- 91 Items for Systematic Reviews and Meta-analyses guidelines (PRISMA) <sup>16</sup>. The protocol of this
- 92 study is available in PROSPERO (CRD42018099518) <sup>17</sup>.

## **Identification and selection of studies**

- 95 We searched the MEDLINE (via Ovid), EMBASE (via Ovid), Web of Science, CENTRAL and
- 96 CCTR (via The Cochrane Library), Physiotherapy Evidence Database (via PEDro website),
- 97 CNKI, VIP, Wan Fang, ClinicalTrials.gov (https://www.clinicaltrials.gov/) and Current
- 98 controlled trials (www.controlled-trials.com) from the inception dates to December 9, 2018,
- 99 using the keywords pulsed electromagnetic fields and osteoporosis. The Open Grey
- 100 (http://www.opengrey.eu/) was searched for the Grey Literature research. The detailed electronic
- search strategies are provided in Supplementary Appendix I. An additional search was performed
- under a mechanism of living systematic review <sup>18</sup> to identify recently published randomized
- clinical trials (RCTs) from December 10, 2018 to April 30, 2021 using the databases and
- 104 keywords described above. The whole procedure was assisted by a librarian from Sichuan
- 105 University.
- Randomised controlled trials or quasi-randomised trials examining the effects of PEMFs
- 107 compared to placebo or sham or other agents for the management of primary osteoporosis
- 108 (including those with previous fractures) were included if they met the inclusion criteria listed in
- Box 1. Studies were excluded if the study population had a diagnosis of corticosteroid-induced
- osteoporosis or other secondary osteoporosis (e.g., rheumatoid arthritis), studies where
- participants had a history of hip replacement or surgery related with osteoporotic fractures, the
- study type was observational studies, review articles, abstracts, conference reports and book
- chapters.
- 114 A three-stage screening methodology was performed to select relevant RCTs for this review.

Primarily, all titles were screened by one reviewer (SYZ) for eligibility and irrelevant papers were excluded accordingly. Secondary, two reviewers (YL and LQW or KPS) independently reviewed each study title and abstract. Thirdly, two independent reviewers (XNX and JMH or XLG) accessed the full text to assess against the eligibility criteria for each potentially eligible study. A third reviewer (CQH or LY) was involved for any disagreement.

## **Assessment of characteristics of studies**

## Quality assessment

The risk of bias was assessed by using the Cochrane Collaboration's 'Risk of bias' tool <sup>15</sup>. Seven key domains were assessed by two reviewers (SYZ and LQW): 1) the randomization sequence generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of outcome assessment, 5) incomplete outcome data, 6) selective reporting, and 7) other bias. The included studies were graded as low, unclear, or a high risk of bias. Methodological quality was assessed with the use of Physiotherapy Evidence Database (PEDro) tool <sup>19</sup>, which was proved reliable <sup>20</sup> and valid <sup>21</sup>. Each criterion in the PEDro scale with a range of 0-10 was scored 1 ("yes") or 0 ("no, don't know/unclear"). Generally, trials with a PEDro summary score of over five. were considered to have adequate methodological quality <sup>22</sup>. Finally, we used Grading of Recommendations, Assessment, Development and Evaluations (GRADE) <sup>23</sup> to describe the overall quality of the body of evidence.

## **Participants**

To be included, studies involved participants were healthy older adults (including those with previous fractures) aged over 50 years with primary osteoporosis <sup>24</sup>, recognized by two distinct types <sup>25</sup>: 1) type I occurred in postmenopausal women; 2) type II, known as senile osteoporosis, occurred in both men and women.

## Interventions

All RCTs applying electromagnetic fields with pulsed signal and extremely low frequencies (between 5 and 300 Hz) for the management of primary osteoporosis were included. The parameters (frequency and intensity) of PEMFs, sessions per week and total duration of the treatment period were recorded to describe the interventions.

## Outcome measures

146

147

148

149

150

151

152

153

154

155

156

157

All outcomes were continuous data and recorded as the percent change from baseline to post-intervention and different follow-up timepoints. To be included, trials had to provide original data or sufficient information about at least one of outcomes on bone mass, number of incident fractures, self-reported data on the changes in balance and quality of life, physical activity and function, and adverse events. Primary outcomes were bone mass (e.g., Bone Marrow Density or Bone Mineral Content) immediately post-intervention and at follow-ups, and number of incident fractures. Secondary outcomes were functional assessments (e.g., Berg Balance Scale, Timed Up and Go test), quality of life (e.g., EuroQoL (EQ 5D)) and adverse events (e.g., falls and death).

# Data extraction and analysis

- Two independent reviewers (SYZ and YL) extracted the following information from eligible studies: lead author; year of publication; original country; subject characteristics; study design; treatment information; intervention protocol; outcome measures; raw outcome data; follow-up
- period and other relevant information. Disagreements were resolved by consensus.
- 162 All meta-analyses were performed using analysis was performed using Review Manager
- 163 (RevMan) software (The Cochrane Collaboration, version 5.4). For each included study, the
- mean difference (MD) of percentage change with 95% confidential intervals (CIs) was calculated
- when the outcome measures were consistent across studies or else the standard mean difference
- 166 (SMD) was calculated instead for continuous outcomes (reporting mean and standard deviation
- 167 (SD) or standard error (SE) of the mean). If the MD was not reported, it was calculated as the
- 168 change between values of the baseline and post-intervention. In the case that the value of SD
- 169 (SD<sub>diff</sub>) was not reported, it was obtained 1) by multiplying SEs of means by the square root of
- the sample size when standard errors (SEs) of the means were reported, or 2) with SDs at the
- baseline ( $SD_{baseline}$ ) and post-intervention SD ( $SD_{post}$ ) in addition to the within-groups bivariate
- 172 correlation coefficient (r) <sup>26</sup>:

$$SD_{diff} = \sqrt{SD_{baseline}^2 + SD_{post}^2 - (2 \times r \times SD_{baseline} \times SD_{post})}$$

- 173 The I<sup>2</sup> statistic was employed for evaluating heterogeneity and a standard Chi<sup>2</sup> test was employed
- 174 for detecting whether significant heterogeneity existed. Heterogeneity was statistically significant

at P < 0.10 after due consideration of I<sup>2</sup> statistic, of which a value greater than 50% was 175 considered substantial heterogeneity <sup>27</sup>. The random-effects model was applied where the 176 177 evidence of heterogeneity was found. 178 The comparison was established between PEMFs and placebo control or exercise in the meta-179 analysis. The subgroup analysis was conducted to detect the effectiveness relative to different 180 follow-up timepoints (postintervention; follow-up at 12, 24 weeks from baseline). To evaluate the 181 quality and consistency of pooled results, the sensitivity analysis was conducted by deleting each 182 included study. Where the data allowed, assessment of publication bias was performed. All tests 183 were two-tailed, and P < 0.05 was considered statistically significant. 184 185 **RESULTS** 186 Flow of studies through the review 187 In total, 806 articles were identified by our search, of which 124 duplicate articles were removed. 188 Based on title and abstract screening, 632 of these articles were excluded. Full texts of 50 articles 189 were read, a further 42 articles were excluded, remaining 8 articles included in the data extraction and analysis of the review (Figure 1) <sup>28-35</sup>. 190 191 192 **Characteristics of studies** 193 Quality 194 All included studies achieved PEDro scores over 5, among which five studies achieved the score over 8 (Table 1)<sup>28,29,31-33</sup>. Of the 8 included studies, 2 studies were rated as 'low risk of bias' in all 195 domains<sup>31,32</sup>, and other studies were classified as 'unclear risk of bias' for at least 1 aspect or 196 197 'high risk of bias' for at least 2 aspects. In results of GRADE, the quality of the evidence for the 198 comparison between PEMFs versus placebo control was low or moderate, and that for the 199 comparison between PEMFs versus exercise was very low. The results of the risk of bias and 200 GRADE are presented in the Supplementary Tables and Figures. 201 202 **Participants** 203 In total, data were extracted for 396 participants, comprising 183 participants in PEMFs group

and 213 participants in placebo control (alendronate/pharmacological therapy) or exercise group.

Mean age ranged from 56.3 to 70 years, with a gender ratio of 49 to 347. Participant characteristics are detailed in Table 2.

#### Intervention

205

206

207

208

215

216

219

220

- The frequency and intensity of PEMFs exposure varied at 8-100 Hz and 1.2-5 mT separately. A
- 210 range of 30-36 PEMFs sessions, with 30-60 min/session, were prescribed for participants, and 4
- 211 to 72 weeks follow-up were conducted across all studies. Control intervention types included
- 212 first-line pharmacological agents (e.g., Alendronate, intake of Vitamin D and Calcium) and
- 213 exercise (e.g., whole body vibration and resistance training). The intervention characteristics of
- 214 the included studies are detailed in the Table 2.

#### Outcome measures

- The outcome measures in each study with the categories of bone mass and functional assessments
- are detailed in Table 2.

## Effect of intervention I: PEMFs versus control group

- 221 Bone Mineral Density (BMD)
- Five studies (study population, N=248)  $^{28,30-33}$  and three studies (study population, N=124)
- 223 <sup>30,32,33</sup> reported data on percentage change in BMD at the lumbar and femur neck respectively
- 224 after intervention directly (Figure 2). Low certainty evidence showed that PEMFs has no effect
- on BMD at the lumbar (MD 0.01; CI -0.04 to 0.06) and femur neck (MD 0.01; CI -0.02 to 0.04)
- with no statistically significant heterogeneity (lumbar:  $I^2 = 0\%$ , P = 0.48; femur neck:  $I^2 = 0\%$ , P = 0.48; femur neck:  $I^2 = 0\%$ ,  $I^2 = 0$
- 227 0.79). Two studies (study population, N=125) <sup>31,32</sup>performed follow-ups at 12 and 24 weeks from
- baseline on percentage change in BMD at the lumbar (Figure 2). Moderate certainty evidence
- showed that there is no statistically significant effect on BMD at the lumbar at the 12 weeks
- 230 follow-up (MD -0.01; CI -0.28 to 0.25) and the 24 weeks follow-up (MD -0.02; CI -0.30 to 0.26)
- with no statistically significant heterogeneity (12 weeks:  $I^2 = 0\%$ , P = 1.00; 24 weeks:  $I^2 = 0\%$ , P = 1.00; 24 weeks:  $I^2 = 0\%$ , P = 1.00; 25 weeks:  $I^2 = 0\%$ ,  $I^2 = 0\%$ ,
- 232 = 0.98). No significant changes in heterogeneity and overall effect were observed in the
- 233 sensitivity analysis.

234

235

## Berg Balance Scale (BBS)

Three studies (study population, N=168)  $^{31,32,35}$ conducted the assessment of BBS after intervention directly (Figure 3). Low certainty evidence showed that there is no statistically significant effect on percentage change in BBS (MD 0.01; CI -0.09 to 0.11) with no statistically significant heterogeneity ( $I^2 = 0\%$ , P = 1.00). Two studies (study population, N=125)  $^{31,32}$ carried out follow-ups at 12 and 24 weeks from baseline on percentage change in BBS (Figure 3). Moderate certainty evidence showed that no statistically significant effect is detected on BBS at the 12 weeks (MD 0.00; CI -0.13 to 0.14) and 24 weeks follow-up (MD -0.00; CI -0.15 to 0.14) with evidence of no statistically significant heterogeneity (12 weeks:  $I^2 = 0\%$ ,  $I^2 = 0.99$ ). No significant changes in heterogeneity and overall effect were observed in the sensitivity analysis.

# Timed Up and Go (TUG) test

Two studies (study population, N=127)  $^{31,35}$ assessed the percentage change in TUG test after intervention directly (Figure 3). Low certainty evidence showed that there is no statistically significant effect on TUG (MD -0.04; CI -0.80 to 0.72) with no statistically significant heterogeneity ( $I^2 = 0\%$ , P = 0.97). No significant changes in heterogeneity and overall effect were observed in the sensitivity analysis.

# Effect of intervention II: PEMFs versus exercise group

Three studies (study population, N=110)  $^{29,33,34}$  investigated the effect of PEMFs on percentage change in BMD at the lumbar and femur neck respectively after intervention directly (Figure 4). Very low certainty evidence showed that PEMFs has small but significant effect on BMD at the femur neck (MD 0.10; CI 0.01 to 0.20), and no effect on BMD at the lumbar (MD 0.15; CI -0.04 to 0.35), both with no statistically significant heterogeneity respectively (femur neck:  $I^2 = 28\%$ , P = 0.25;  $I^2 = 47\%$ , P = 0.15). In the sensitivity analysis, one study  $^{29}$ was found to be a contributor to results of non-significant heterogeneity and the effect on BMD at the femur neck. After excluding the study, the heterogeneity was reduced to 0% (femur neck: P = 0.96; P = 0.86), and the small but significant effect on BMD at the femur neck was eliminated (MD 0.00; CI -0.15 to 0.16).

# **DISCUSSION**

This systematic review and meta-analysis of 8 studies involving 396 participants demonstrated PEMFs as a physical therapy was non-inferior to conventional pharmacological agents in preventing the decline of BMD and balance function for the management of primary osteoporosis in older adults. Meanwhile, we also found that PEMFs might be slightly more effective in increasing BMD than exercise. According to our knowledge, no systematic review and metaanalysis was initiated before, except one network meta-analysis exploring effects of nonpharmacological interventions including PEMFs on balance function only <sup>36</sup>, and several narrative reviews including clinical studies were retrieved <sup>11,37,38</sup>. Our results are in consistent with findings from previous reviews 11,36,37 that PEMFs achieved positive effects on BMD and balance function for older adults with primary osteoporosis, implicating that PEMFs may potentially become a promising treatment option. Bisphosphonates and exercise were both identified as the first-line interventions for the management of osteoporosis in the latest evidence-based guideline <sup>10</sup>. Our study established comparisons between PEMFs and active placebo or exercise based on groups set by included studies, and sub-group analysis was stratified by different intervals between the baseline, postintervention, and follow-ups. BMD, as a surrogate measure for therapeutic effectiveness, can be assessed by various methods, among which dual x-ray absorptiometry (DXA) was proved to be reliable in the diagnosis of osteoporosis and have relatively good responsiveness in RCT <sup>39,40</sup>. Our study demonstrated that there was no difference between PEMFs and active placebo in improving BMD at the lumbar and femur neck in all sub-group meta-analysis, which suggests PEMFs is nearly effective as pharmacological agents for osteoporosis, and the effect could last for at least 24 weeks. Moreover, the effects of PEMFs versus exercise on BMD at the lumbar was not significant, while that was detected as small but significant on BMD at the femur neck. Our results were considered fairly stable as the sensitivity analysis only detected one study <sup>29</sup> affecting the heterogeneity and effect of PEMFs versus exercise on BMD at the femur neck. This is likely due to variations in exercise characteristics (e.g., duration, training load and training volume). Therefore, this part of results should be interpreted with caution. Impaired balance function is an important risk factor increasing the incidence of falling and fracture, which is modifiable by balance-improving interventions <sup>41</sup>. In line with results on BMD, no statistically significant difference was observed for balance function measured by BBS and TUG after the intervention of PEMFs versus active placebo. In the sub-group analysis, the effect

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

of PEMFs on BBS at 12, 24 weeks follow-up was also not statistically significant, confirming that PEMFs is as effective as conventional pharmacological agents in improving balance function which could last for 24 weeks. In consistent with a previous systematic review <sup>36</sup>, it reported that PEMFs exert positive effect on BBS and TUG tests reflecting balance function. However, the network meta-analysis was conducted to further compare the effects of five interventions on balance function with the conclusion that balance and strength training was better than other interventions. Only one study using data on PEMFs was included in the analysis, compared to that we included 3 studies, and no study was ever conducted to directly compare the effect of PEMFs versus other non-pharmacological interventions on balance function, combining these two may explain, in part, the conflicting results. Furthermore, our sensitivity analysis detecting no changes in levels of heterogeneity and effect confirmed our results as relatively robust. To overcome the shortcomings of the "statistically significant difference", the minimum clinically important difference (MCID) defined as "the smallest change that is important to patients" is employed to generate a threshold value for such change 42. Any patient whose responses help them reach the MCID threshold is considered as responders. Thus, a certain proportion of responders to the total participants involved in a trialed intervention indicates the likelihood of patients under the same condition also responding favorably to the same intervention <sup>43</sup>. However, no definite consensus reached on the MCID of BMD and balance function. Some evidence showed that changes by 2-5% at the lumbar and 8% at the proximal femur <sup>44</sup>, a point-drop in BBS associated with a 3-4% increase in risk of falling <sup>45</sup>, and an improvement of 2-3 seconds in TUG test were considered as MCID for the older population <sup>46</sup>. In our study, no study included used the MCID and responder rate to evaluate the effect of PEMFs, thus, it is hard to determine the clinical importance of improvements achieved by PEMFs on BMD and balance function compared with placebo and exercise. Furthermore, the successful treatment of osteoporosis is prevention of fractures, while no treatment can completely eliminate fracture risk <sup>10</sup>. Although a certain increase in BMD and the improvement in balance function for osteoporosis may result in a reduction in fracture risk, no risk and number of incident fracture were reported in studies included in our review. Therefore, studies with reporting measures of MCID, fracture risk and incidence in the future are required to further confirm that the effect of PEMFs in treating osteoporosis is of clinical importance to clinicians and patients. This review has several strengths. To date, we are the first to conduct a systematic review and

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

meta-analysis to explore the effect of PEMFs on BMD and balance function for primary osteoporosis. Secondary, the results of our study were fairly stable due to studies included were of appropriate methodological quality, and no significant heterogeneity was found in the analysis. Furthermore, a key finding of this review was that PEMFs as an intervention alone achieved an effect non-inferior to first-line treatment (pharmacological agents and exercise) on improvements in BMD and balance function for older adults with primary osteoporosis. At last, a librarian familiar with the development of searches and a mechanism of living systematic review were involved over a course of 3 years to ensure no study was missed in compliance with the study protocol. There are several limitations to this review that deserve consideration. The primary limitation of our review was the limited number of included studies with only 8 studies comprising of 396 participants for the analysis, from which the level of evidence generated were moderate to very low. In some sub-group analyses, only 2-3 studies were included from which some uncertainty in the results interpretation may exist based on data extracted. In addition, as the maximum PEMF treatment session lasted for 16 weeks and the longest follow-up was 24 weeks for the analysis, the error among the minimum percentage change in BMD and balance function may stay undetectable and further deepened the uncertainty 44. Furthermore, the clinical relevance of the findings was limited, combined with no study reported data on MCID, responder rate and incident fracture and only two studies <sup>31,32</sup>included used intention-to-treat (ITT) analysis. According to accumulated evidence <sup>11,47</sup>, the parameters of non-pharmacological interventions, including intensity, frequency, and duration, were critical to impact changes in outcome measures for osteoporosis, while our study could not conduct the sub-group analysis based on different parameters due to limited information retrieved. Another potential limitation was the systematic search was limited to English and Chinese manuscripts available in full text, and some relevant trials may be missed.

## CONCLUSION

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

In summary, moderate to very low certainty evidence showed that PEMFs as an intervention alone has positive effects non-inferior to first-line treatment (pharmacological agents and exercise) on BMD and balance function in older adults with primary osteoporosis and should be considered as a promising option in the management of osteoporosis. Although uncertainty about responses

to the intervention and changes in outcome measures may be existed but undetectable, our findings may still be fairly stable as we consistently found similar results in the primary and sensitivity analyses. For further deeply confirming the effect of PEMFs for osteoporosis, adding endpoints like fracture risk and incidence, and outcome measures like MCID and responder rate to the core collection are necessary. In the future, researchers planning a PEMFs study should optimize the study design, with taking factors not limited to undetectable errors under outcomes, parameters of interventions, longer follow-up period, larger sample size and ITT analysis into consideration, to generate high certainty evidence.

## **DECLARATIONS**

## Acknowledgements

- We are grateful for the partnership and support from the library of Sichuan University for the
- development of search strategy, also and the clinical research and statistics office of West China
- Hospital for data processing and analysis.

#### Funding

360

361

362

363

364

365

366

367

368

369

370

371

375

376

383

384

386

387

- 377 This study was supported by the National Natural Science Foundation (81972146 to Chengqi He,
- and 82002393 to Siyi Zhu), the Department of Science and Technology of Sichuan Province
- 379 (2020YJ0210 to Chengqi He, 2021YFS0004 and 2021YJ0424 to Siyi Zhu), China Postdoctoral
- 380 Science Foundation (2020M673251), Health Commission of Sichuan Province (20PJ034), and
- West China Hospital of Sichuan University (2019HXBH058 to Siyi Zhu). The funders played no
- role in the design, conduct, or reporting of this study.

## **Availability of Data and Materials**

Not applicable

#### **Authors' contributions**

- 388 All authors have made substantial contributions to the study design. SYZ and YL have
- 389 contributed to the ongoing data collection. All listed authors have contributed to the drafting of
- 390 the manuscript.

# **Competing interests**

391

392

394

395

The authors declare that they have no competing interests.

## REFERENCES

- 1. Eastell R, O'Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. *Nature reviews Disease primers*. 2016;2:16069.
- 398 2. International Osteoporosis Foundation. EPIDEMIOLOGY OF OSTEOPOROSIS AND
  399 FRAGILITY FRACTURES. https://www.osteoporosis.foundation/facts400 statistics/epidemiology-of-osteoporosis-and-fragility-fractures. Published 2021. Accessed
  401 May 12, 2021.
- Bessette L, Ste-Marie L-G, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. *Osteoporosis International*. 2008;19(1):79-86.
- 404 4. International Osteoporosis Foundation. KEY STATISTICS FOR ASIA.
   405 https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-asia. Published 2021.
   406 Accessed May 12, 2021.
- 407 5. US D. Bone health and osteoporosis: A Report of the Surgeon General. http://www.surgeongeneral.gov/library/bonehealth/content html. 2004.
- 409 6. Burge R, Dawson □ Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence
   410 and economic burden of osteoporosis □ related fractures in the United States, 2005–2025.
   411 Journal of bone and mineral research. 2007;22(3):465-475.
- 412 7. Kanis J, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. *Osteoporosis international*. 2005;16(3):229-238.
- 414 8. Kanis J, Group WS. Assessment of Osteoporosis at the Primary Health Care Level. Geneva. *World Health Organization*. 2008.
- 416 9. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *Pharmacy and Therapeutics*. 2018;43(2):92.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical
   Endocrinologists/American College of Endocrinology clinical practice guidelines for the
- diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocrine Practice*. 2020;26:1-46.
- Zhu S, He H, Zhang C, et al. Effects of pulsed electromagnetic fields on postmenopausal osteoporosis. *Bioelectromagnetics*. 2017;38(6):406-424.
- 424 12. Petecchia L, Sbrana F, Utzeri R, et al. Electro-magnetic field promotes osteogenic
- differentiation of BM-hMSCs through a selective action on Ca 2+-related mechanisms. *Scientific reports.* 2015;5:13856.
- Vincenzi F, Targa M, Corciulo C, et al. Pulsed electromagnetic fields increased the antiinflammatory effect of A2A and A3 adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. *PloS one*. 2013;8(5):e65561.
- 430 14. Andrew C, Bassett L, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively coupled electromagnetic fields. *Science*. 1974;184(4136):575-577.
- Higgins JP, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons; 2019.
- 434 16. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.

- 436 17. Siyi Z, Wei X, Hongchen H, et al. Pulsed electromagnetic fields (PEMFs) for preventing
- and treating primary osteoporosis: systematic review and meta-analysis of randomized controlled trials. PROSPERO 2018 CRD42018099518.
- https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42018099518.
- 440 Published 2021. Accessed May 16, 2021.
- 441 18. Cochrane Library. Living systematic reviews. https://community.cochrane.org/review-production/production-resources/living-systematic-
- reviews#:~:text=Living%20Evidence%20Network-
- 444 ,What% 20is% 20a% 20living% 20systematic% 20review% 3F,the% 20evidence% 20(i.e.% 20 monthly% 20searches). Published 2021. Accessed May 16, 2021.
- Sherrington C, Herbert R, Maher C, Moseley A. PEDro. A database of randomized trials and systematic reviews in physiotherapy. *Manual therapy*. 2000;5(4):223-226.
- 448 20. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. *Physical therapy*. 2003;83(8):713-450 721.
- de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. *Australian Journal of Physiotherapy*. 2009;55(2):129-133.
- da Costa BR, Hilfiker R, Egger M. PEDro's bias: summary quality scores should not be used in meta-analysis. *Journal of clinical epidemiology*. 2013;66(1):75-77.
- 456 23. Group GW. Grading quality of evidence and strength of recommendations. *BMJ: British Medical Journal*. 2004;328(7454):1490.
- Soen S, Fukunaga M, Sugimoto T, et al. Diagnostic criteria for primary osteoporosis: year 2012 revision. *Journal of bone and mineral metabolism.* 2013;31(3):247-257.
- 460 25. Glaser DL, Kaplan FS. Osteoporosis: definition and clinical presentation. *Spine*. 1997;22(24):12S-16S.
- 462 26. Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect.
  463 *Cochrane handbook for systematic reviews of interventions.* 2019:143-176.
- 464 27. Sedgwick P. Meta-analyses: what is heterogeneity? *Bmj.* 2015;350:h1435.
- 465 28. Abdelaal AA, Taha MM, Amin DI, Draz AH. Effect of pulsed electromagnetic therapy versus low-level laser therapy on bone mineral density in the elderly with primary
- osteoporosis: a randomized, controlled trial. *Bulletin of Faculty of Physical Therapy*. 2017;22(1):34-39.
- Elsisi HFEM, Mousa GSM, ELdesoky MTM. Electromagnetic field versus circuit weight training on bone mineral density in elderly women. *Clinical interventions in aging*.
   2015;10:539.
- 472 30. Giordano N, Battisti E, Geraci S, et al. Effect of electromagnetic fields on bone mineral density and biochemical markers of bone turnover in osteoporosis: a single-blind, randomized pilot study. *Current Therapeutic Research*. 2001;62(3):187-193.
- 475 31. Liu H, Liu Y, Yang L, Wang C, Wu Y, He C. Curative effects of pulsed electromagnetic 476 fields on postmenopausal osteoporosis. *Sheng wu yi xue gong cheng xue za zhi= Journal* 477 *of biomedical engineering= Shengwu yixue gongchengxue zazhi.* 2014;31(1):48-52.
- 478 32. Liu HF, Yang L, He HC, et al. Pulsed electromagnetic fields on postmenopausal
   479 osteoporosis in southwest China: A randomized, active □ controlled clinical trial.
   480 Bioelectromagnetics. 2013;34(4):323-332.
- Shanb AA, Youssef EF, Muaidi QI, Alothman AA. Whole body vibration versus magnetic therapy on bone mineral density in elderly osteoporotic individuals. *Journal of*

- *back and musculoskeletal rehabilitation.* 2017;30(4):903-912.
- Shanb A-SA, Youssef EF, El-Barkouky MG, Kamal RM, Tawfick AM. The effect of magnetic therapy and active exercise on bone mineral density in elderly women with osteoporosis. *Journal of Musculoskeletal Research*. 2012;15(03):1250016.
- Wu Y-C, Xu J, Yang L, Xiong E-F, Xie W, He C-Q. The effect of low-frequency pulsed electromagnetic fields on balance ability of patients with post-menopausal osteoporosis.

  Sichuan da xue xue bao Yi xue ban= Journal of Sichuan University Medical science edition. 2014;45(1):116-119.
- Zhu L, Wu W, Chen M, et al. Effects of Nonpharmacological Interventions on Balance
   Function in Patients with Osteoporosis or Osteopenia: A Network Meta-Analysis of
   Randomized Controlled Trials. Evidence-Based Complementary and Alternative
   Medicine. 2021;2021.
- Wang R, Wu H, Yang Y, Song M. Effects of electromagnetic fields on osteoporosis: a systematic literature review. *Electromagnetic biology and medicine*. 2016;35(4):384-390.
- Wang T, Yang L, Jiang J, et al. Pulsed electromagnetic fields: promising treatment for osteoporosis. *Osteoporosis International*. 2019;30(2):267-276.
- Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. *Postgraduate medical journal*. 2007;83(982):509-517.
- 501 40. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. *Journal of bone and mineral research*. 1994;9(8):1137-1141.
- 503 41. Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a 504 systematic review of recent 10 years and meta-analysis. *Journal of the American Medical* 505 *Directors Association*. 2012;13(2):188. e113-188. e121.
- 506 42. Stratford PW, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to change of the Roland-507 Morris back pain questionnaire: part 1. *Physical therapy*. 1998;78(11):1186-1196.
- Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. *Pain.* 2000;88(3):287-294.
- 510 44. Cranney A, Welch V, Wells G, et al. Discrimination of changes in osteoporosis outcomes.
  511 *The Journal of rheumatology.* 2001;28(2):413-421.
- 512 45. Shumway-Cook A, Baldwin M, Polissar NL, Gruber W. Predicting the probability for falls in community-dwelling older adults. *Physical therapy*. 1997;77(8):812-819.
- Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. *Journal of the American geriatrics Society.* 1991;39(2):142-148.
- 516 47. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database of Systematic Reviews*. 2002(2). 518

# Box of inclusion criteria for eligible studies

#### Box 1. Inclusion criteria

#### Design

520

521 522 523

526

- Randomised or quasi-randomised controlled trial
- · Published in a peer-reviewed journal
- Full text available in Chinese and English

#### **Participants**

 Healthy older adults (including those with previous fractures) aged over 50 years with primary osteoporosis

#### Intervention

• Electromagnetic fields with pulsed signal and extremely low frequencies (between 5 and 300 Hz)

## Outcome measures

- Primary outcomes: bone mass, number of incident fractures
- Secondary outcomes: Functional assessments, quality of life, adverse events

#### Comparisons

- PEMFs versus sham/nothing
- PEMFs versus placebo/pharmacological agents
- PEMFs versus exercise/other physical agent or intervention
- PEMFs plus other intervention versus other intervention

**Table 1** PEDro scores of included studies.

Study	Eligibility criteria and source	Random allocation	Conceale d allocation	Baseline comparab ility	Blind subjects	Blind therapists Blind	Blind assessors	Adequate follow-up	Intention- to-treat analysis	Between- group comparis ons	Point estimates and variability	Total score (0 to 10)
Liu Hf et al, 2013 <sup>32</sup>	Y	Y	Y	Y	N	N	Y	Y	Υ	Y	Y	9
Liu Hf et al, 2014 <sup>31</sup>	Y	Υ	Υ	Υ	N	N	N	Y	Υ	Υ	Y	8
Shanb et al, 2017 <sup>33</sup>	Y	Υ	Υ	Υ	N	N	Υ	Y	N	Υ	Y	8
Shanb et al, 2012 <sup>34</sup>	Y	Υ	N	N	N	N	N	Y	N	Υ	Y	5
Elsisi et al, 2015 <sup>29</sup>	Y	Υ	Y	N	Y	Υ	Y	Y	N	Υ	Y	9
Giordano et al, 2001 <sup>30</sup>	Υ	Υ	N	Υ	N	N	Υ	Υ	N	Υ	Υ	7
Wu Yc et al, 2014 <sup>35</sup>	Y	Υ	N	Y	N	N	N	Y	N	Υ	Υ	6
Ashraf et al, 2017 <sup>28</sup>	Y	Y	Υ	Υ	N	N	Υ	Y	N	Y	Y	8

**Table 2** Characteristics of the included studies.

Study		Pa	articipant		Int	ervention		Follow-		
	Sample size	Study arms	Age (y)	Male/Female	Type of intervetion	Dose per protocol <sup>a</sup>	Primary	Secondary	Efficacy/Effect	up
Liu Hf et al, 2013 <sup>32</sup>	41	1. PEMFs (n=20) 2. AL (n=21)	61.70 (1.34) 63.14 (4.32)	0/41	PEMFs	3.82 mT, 8 Hz, 40min/session for a total of 30 sessions.	BMDL	BMDF; 25(OH)D; LE MMT; BBS	Effective as alendronate.	24 weeks
Liu Hf et al, 2014 <sup>31</sup>	84	1. PEMFs (n=44) 2. AL (n=40)	62.41 (5.47) 62.63 (4.54)	0/84	PEMFs	3.8 mT, 8-12 Hz, 40min/session for a total of 30 sessions.	BMDL; BMDF	VAS; TUG; BBS	Effective as alendronate.	72 weeks
Shanb et al, 2017 <sup>33</sup>	68	1. PEMFs (n=25) 2. WBV (n=25) 3. AL (n=18)	63.9 (3.9) 64.1 (4.4) 64.5 (4.03)	23/45	PEMFs	5 mT, 33 Hz, 50 min/session, 2 sessions/week for 16 weeks.	BMDL; BMDF	Serum calcium and vitamin D	Effective in conjunction with pharmacological treatment.	N/A
Shanb et al, 2012 <sup>34</sup>	30	1. PEMFs (n=15) 2. Exercise (n=15)	60-70	0/30	PEMFs	5 mT, 33 Hz, 50 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	N/A	Effective as exercise.	N/A
Elsisi et al, 2015 <sup>29</sup>	30	1. PEMFs (n=15) 2. CRT- Exercise (n=15)	64.73 (3.08) 65.13 (2.44)	0/30	PEMFs	5 mT, 33 Hz, 30 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	N/A	More effective than CRT exercise.	N/A
Giordan o et al, 2001 <sup>30</sup>	40	1. PEMFs (n=20) 2. Placebo (n=20)	56.3 (4.0) 55.9 (3.1)	0/40	PEMFs	1.2 mT, 100 Hz, 60 min/session, 3 sessions/week for 12 weeks.	BMDL; BMDF	Serum and urinary calcium, phosphate; Serum ALP, osteocaltin and PICP; Urinary hydroxyproline	Not effective in increasing BMD, but effective in stimulating osteogenesis.	1 month
Wu Yc et al, 2014 <sup>35</sup>	43	1. PEMFs (n=24) 2. AL (n=19)	59.08 (4.65) 59.53 (5.40)	0/43	PEMFs	3.8 mT, 8-12 Hz, 40min/session for a total of 30 sessions.	TUG; BBS; Balance function	N/A	Effective as alendronate.	N/A

Ashraf et 60 al, 2017 <sup>28</sup>	(n= 2. l (n=	⁄led	59.85 (2.35) 60.20 (2.17) 60.00 (2.62)	26/34	PEMFs	4 mT, 33 Hz, 30 min/session, 3 sessions/week for 12 weeks.	BMDL	N/A	More effective than LLLT and AL group.	N/A
2	,	_0)								

<sup>&</sup>lt;sup>a</sup>Waveforms; Intensity; Frequency; Duration (weeks).

bAbbreviations. PEMFs=Pulsed electromagnetic fields, AL=alendronate, WBV=Whole body vibration, CRT=Circuit weight training, LLLT=low-level laser therapy, mT=millitesla, Hz=Hertz, BMDL=lumbar bone mineral density, BMDF=femur bone mineral density, 25(OH)D=serum 25OH vitamin, LE MMT=total lower-extremity manual muscle test, BBS=Berg Balance Scale, VAS=Visual Analogue Scale, N/A=not applicable, TUG=Timed Up and Go, ALP=Alkaline Phosphatase, PICP=Procollagen type I carboxy-terminal propeptide, Med=Medication.







Figure 1. PRISMA flow of studies through the review.




**Figure 2.** Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.



**Figure 3.** Forest plot analysis of the effects of PEMFs on balance function measured by BBS (A) and TUG test (B) compared with placebo control. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BBS = Berg Balance Scale; TUG = Timed Up and Go; PEMFs = Pulsed Electromagnetic Fields.





**Figure 4.** Forest plot analysis of the effects of PEMFs on BMD at the lumbar (A) and femur neck (B) compared with exercise group. Data are presented as mean difference (MD) between treatment and control groups with a 95% confidence interval (CI). SD = Standard Deviation; BMD = Bone Mineral Density; PEMFs = Pulsed Electromagnetic Fields.